Strongbridge Biopharma plc Announces Presentations at Two Upcoming Investor Conferences
August 28 2018 - 7:31AM
Strongbridge Biopharma plc, (Nasdaq: SBBP), a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs, today announced that Matthew
Pauls, president and chief executive officer, is scheduled to
present a corporate overview at two upcoming investor conferences.
The details are as follows:
H.C. Wainwright 20th Annual Global Investment
Conference Date: Wednesday, September 5, 2018
Time: 12:05 p.m. ET Location: St. Regis Hotel, New York,
NY
2018 Wells Fargo Healthcare Conference
Date: Thursday, September 6, 2018 Time: 3:05 p.m. ET
Location: Westin Copley Place, Boston, MA
Both presentations will be webcast live and available on the
“Events & Presentations” page in the Investor section of the
Company’s website at www.strongbridgebio.com.
About Strongbridge
BiopharmaStrongbridge Biopharma is a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs. Strongbridge's rare endocrine
franchise includes MACRILEN™ (macimorelin), the first and
only FDA-approved oral drug indicated for the diagnosis of
adult growth hormone deficiency, RECORLEV™ (levoketoconazole), a
cortisol synthesis inhibitor currently being studied in Phase 3
clinical studies for the treatment of endogenous Cushing's
syndrome, and veldoreotide extended release, a pre-clinical
next-generation somatostatin analog being investigated for the
treatment of acromegaly and potential additional applications in
other conditions amenable to somatostatin receptor activation.
MACRILEN has orphan drug exclusivity in the United States, and
both RECORLEV and veldoreotide have received orphan drug
designation from the FDA and the European Medicines
Agency. The Company’s rare neuromuscular franchise includes
KEVEYIS® (dichlorphenamide), the first and only FDA-approved
treatment for hyperkalemic, hypokalemic, and related variants of
primary periodic paralysis. KEVEYIS has orphan drug exclusivity
in the United States.
Contacts:
Corporate and Media Relations Elixir Health
Public Relations Lindsay Rocco +1 862-596-1304
lrocco@elixirhealthpr.com
Investor Relations
U.S.:Solebury Trout Marcy Nanus +1 646-378-2927
mnanus@soleburytrout.com
Europe:First HouseGeir Arne Drangeid +47 913 10
458strongbridgebio@firsthouse.no Strongbridge Biopharma plc900
Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1
610-254-9200 Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Jul 2023 to Jul 2024